Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial

Archives of Drug Information

Volumn 3, Issue 1, 2010, Pages 9-18

  Lotti, Torello ^a   Chimenti, Sergio ^b   Katsambas, Andreas ^c   Ortonne, Jean Paul ^d   Dubertret, Louis ^e   Licu, Daiana ^f   Simon, Jan ^g  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF ATHENS   (Greece)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f MERCK SERONO S A   (Switzerland)

^g UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Efalizumab; Psoriasis; Safety; Treatment efficacy

Indexed keywords

EFALIZUMAB;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; BLOOD DISEASE; BRONCHITIS; CONNECTIVE TISSUE DISEASE; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE DISEASE; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HERPES SIMPLEX; HUMAN; IMMUNOPATHOLOGY; INFESTATION; INFLUENZA; INJURY; INNER EAR DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; RATING SCALE; RHINOPHARYNGITIS; SKIN CARCINOMA; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; THORAX DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE;

EID: 78851469900     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2009.00026.x     Document Type: Article

References (16)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71.
2. Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, etal. Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006;24(suppl 40):S72-8.
3. Langley RG, Krueger GG, Griffiths CE. Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(suppl 2):ii18-ii23.
4. Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, etal. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): Mechanisms of action. Dermatology 2004;208:297-306.
5. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, etal. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
6. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, etal. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 2003;290:3073-80.
7. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, etal. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized Phase III trial. J Am Acad Dermatol 2005;52:425-33.
8. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, etal. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8.
9. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, etal. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a Phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170-81.
10. Sterry W, Stingl G, Langley RG, Zacharie H, Lahfa M, Giannetti A, etal. Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from extended treatment in an international, Phase III, placebo-controlled trial. J Dtsch Dermatol Ges 2006;4:947-56.
11. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008;158:1107-16.
12. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): A comparison. J Drugs Dermatol 2003;2:260-6.
13. Ricardo RR, Rhoa M, Orenberg EK, Li N, Rundle AC, Caro I. Clinical benefits in patients with psoriasis after efalizumab therapy: Clinical trials versus practice. Cutis 2004;74:193-200.
14. Fredriksson T, Pettersson U. Severe psoriasis-Oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
15. Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, etal. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004;3:614-24.
16. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-10.